FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2502201430> ?p ?o ?g. }

• W2502201430 endingPage "675" @default.
• W2502201430 startingPage "667" @default.
• W2502201430 abstract "Flavonoids from medicinal plants have been used in traditional medicine to treat a variety of prevalent diseases. Flavones activate the signaling pathways promoting fuel metabolism and insulin sensitizing in hepatocytes and adipocytes, which suggests that flavones may have the potential to exert in vivo antidiabetic and antihyperlipidemic effects. Thus, the aim of the current study was to determine the antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in diabetic rats. Also, to understand the mechanism involved using in vitro 3T3-L1 cells and tissues from experimental animals treated with test samples through molecular profile studies. Non insulin-dependent diabetic mellitus (NIDDM) rats were treated over a short period (for 10 days) with 60mg/Kg/day of tilianin. After treatment, a biochemical blood profile was determined. Also, adipose and thoracic aortic tissues were used to determine pro-inflammatory profile, adiponectin and adhesion molecules by real-time PCR. In 3T3-L1 cells pretreated with tilianin (10μM), PPARα, PPARγ, GLUT4, FATP-1 and ACSL-1 mRNA expression were measured. In order to explain the potential PPARα interaction with tilianin, a docking study with PPARα was carried out. Thus, intragastric administration of tilianin and metformin induced a decrease in plasma glucose (GLU) in diabetic rats on day 6, and remained significantly lower until the end of the treatment; also blood triacylglycerides (TAG) and cholesterol (CHOL) (p<0.05) were diminished. Moreover, IL-1β and IL-18 expression was significantly decreased in adipose tissue (p<0.05); meanwhile adiponectin was significantly overexpressed (p<0.05). Besides, ICAM-1 expression was significantly reduced in aortic tissue (p<0.05). In 3T3-L1 cells it was found that tilianin increased PPARα and ACSL1 mRNA levels (p<0.05). Finally, tilianin docking studies with PPARα showed polar interactions with Glu269, Tyr314, His 440 and Tyr464 residues. In conclusion, short-term tilianin treatment might exert its antidiabetic and antihyperlipidemic effect by modulating a pro-inflammatory profile, and increasing adiponectin expression. In addition, our results suggest the possible interaction of tilianin with PPARα." @default.
• W2502201430 created "2016-08-23" @default.
• W2502201430 creator A5037631807 @default.
• W2502201430 creator A5049170836 @default.
• W2502201430 creator A5050504925 @default.
• W2502201430 creator A5055994447 @default.
• W2502201430 creator A5060284897 @default.
• W2502201430 creator A5065517754 @default.
• W2502201430 creator A5072630267 @default.
• W2502201430 creator A5073738930 @default.
• W2502201430 creator A5079680878 @default.
• W2502201430 creator A5080891200 @default.
• W2502201430 date "2016-10-01" @default.
• W2502201430 modified "2023-10-18" @default.
• W2502201430 title "Antidiabetic, antihyperlipidemic and anti-inflammatory effects of tilianin in streptozotocin-nicotinamide diabetic rats" @default.
• W2502201430 cites W1080222946 @default.
• W2502201430 cites W1529862612 @default.
• W2502201430 cites W1920695003 @default.
• W2502201430 cites W1963921139 @default.
• W2502201430 cites W1968041660 @default.
• W2502201430 cites W1983297962 @default.
• W2502201430 cites W1998024601 @default.
• W2502201430 cites W1998221258 @default.
• W2502201430 cites W2008381613 @default.
• W2502201430 cites W2027436783 @default.
• W2502201430 cites W2036622936 @default.
• W2502201430 cites W2041880968 @default.
• W2502201430 cites W2044888109 @default.
• W2502201430 cites W2054766191 @default.
• W2502201430 cites W2057414751 @default.
• W2502201430 cites W2067514854 @default.
• W2502201430 cites W2070665653 @default.
• W2502201430 cites W2071692398 @default.
• W2502201430 cites W2073336335 @default.
• W2502201430 cites W2079379175 @default.
• W2502201430 cites W2088248157 @default.
• W2502201430 cites W2097492496 @default.
• W2502201430 cites W2109178003 @default.
• W2502201430 cites W2130064617 @default.
• W2502201430 cites W2130764919 @default.
• W2502201430 cites W2134705852 @default.
• W2502201430 cites W2137046761 @default.
• W2502201430 cites W2148019592 @default.
• W2502201430 cites W2160741950 @default.
• W2502201430 cites W2164280790 @default.
• W2502201430 cites W2165601025 @default.
• W2502201430 cites W2165809374 @default.
• W2502201430 cites W2170651004 @default.
• W2502201430 cites W4294216491 @default.
• W2502201430 doi "https://doi.org/10.1016/j.biopha.2016.07.023" @default.
• W2502201430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27470567" @default.
• W2502201430 hasPublicationYear "2016" @default.
• W2502201430 type Work @default.
• W2502201430 sameAs 2502201430 @default.
• W2502201430 citedByCount "33" @default.
• W2502201430 countsByYear W25022014302016 @default.
• W2502201430 countsByYear W25022014302017 @default.
• W2502201430 countsByYear W25022014302018 @default.
• W2502201430 countsByYear W25022014302019 @default.
• W2502201430 countsByYear W25022014302020 @default.
• W2502201430 countsByYear W25022014302021 @default.
• W2502201430 countsByYear W25022014302022 @default.
• W2502201430 countsByYear W25022014302023 @default.
• W2502201430 crossrefType "journal-article" @default.
• W2502201430 hasAuthorship W2502201430A5037631807 @default.
• W2502201430 hasAuthorship W2502201430A5049170836 @default.
• W2502201430 hasAuthorship W2502201430A5050504925 @default.
• W2502201430 hasAuthorship W2502201430A5055994447 @default.
• W2502201430 hasAuthorship W2502201430A5060284897 @default.
• W2502201430 hasAuthorship W2502201430A5065517754 @default.
• W2502201430 hasAuthorship W2502201430A5072630267 @default.
• W2502201430 hasAuthorship W2502201430A5073738930 @default.
• W2502201430 hasAuthorship W2502201430A5079680878 @default.
• W2502201430 hasAuthorship W2502201430A5080891200 @default.
• W2502201430 hasConcept C126322002 @default.
• W2502201430 hasConcept C134018914 @default.
• W2502201430 hasConcept C170493617 @default.
• W2502201430 hasConcept C171089720 @default.
• W2502201430 hasConcept C185592680 @default.
• W2502201430 hasConcept C187345961 @default.
• W2502201430 hasConcept C2776188179 @default.
• W2502201430 hasConcept C2776292868 @default.
• W2502201430 hasConcept C2776782570 @default.
• W2502201430 hasConcept C2777391703 @default.
• W2502201430 hasConcept C2778270857 @default.
• W2502201430 hasConcept C2779280383 @default.
• W2502201430 hasConcept C2779306644 @default.
• W2502201430 hasConcept C2780152017 @default.
• W2502201430 hasConcept C2780323712 @default.
• W2502201430 hasConcept C43617362 @default.
• W2502201430 hasConcept C4733338 @default.
• W2502201430 hasConcept C555293320 @default.
• W2502201430 hasConcept C71924100 @default.
• W2502201430 hasConcept C98274493 @default.
• W2502201430 hasConceptScore W2502201430C126322002 @default.
• W2502201430 hasConceptScore W2502201430C134018914 @default.
• W2502201430 hasConceptScore W2502201430C170493617 @default.
• W2502201430 hasConceptScore W2502201430C171089720 @default.

• next